Associated Papers
Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary.
Cavazzoni A et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy, 2024
Trans-activating mutations of the pseudokinase ERBB3.
Koivu MKA et al.
Oncogene, 2024
38806620 (PubMed )
Supplement: 41388_2024_3070_MOESM3_ESM.xlsx › Processed_PacBio_data
Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer.
Yu H et al.
Frontiers in Oncology, 2022
36072793 (PubMed )
Supplement: Table_3.xlsx › somatic_alterations
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches.
Laprovitera N et al.
Frontiers in Cell and Developmental Biology, 2021
Contribution of allelic imbalance to colorectal cancer.
Palin K et al.
Nature Communications, 2018
30202008 (PubMed )
Supplement: 41467_2018_6132_MOESM11_ESM.xlsx › Somatic_mutations_in_234_MSS_CR
Select a paper to view details